expect
year
bear
mind
predict
ceil
life
expect
repeatedli
wrong
extrapol
could
reach
year
six
decad
major
reason
steadi
increas
life
expect
greater
control
infecti
diseasesthi
led
decreas
earli
mortal
one
four
children
use
reach
age
also
provid
longer
lifespan
adult
decreas
exposur
acut
chronic
inflammatori
process
vaccin
serv
extrem
well
need
twentiethcenturi
societi
member
life
expect
approxim
year
elimin
mani
infecti
diseas
use
caus
million
death
vaccin
contribut
increas
lifespan
fig
key
contribut
made
vaccin
includ
erad
smallpox
planet
almost
complet
elimin
poliomyel
decreas
incid
diseas
diphtheria
tetanu
pertussi
measl
mump
rubella
recent
vaccin
hepat
hepat
b
haemophilu
influenza
type
b
pneumococcu
decreas
mortal
caus
infecti
diseas
key
question
articl
whether
vaccin
abl
significantli
contribut
health
need
member
twentyfirst
centuri
societi
current
lifespan
year
predict
futur
lifespan
year
today
develop
countri
low
proport
children
young
adult
high
proport
elderli
peopl
fig
composit
quit
differ
one
vaccin
develop
today
societi
clearli
quit
differ
medic
need
answer
question
whether
vaccin
abl
contribut
need
twentyfirst
centuri
societi
need
look
health
need
societi
ask
whether
technolog
address
need
describ
main
stage
life
health
need
age
group
twentyfirst
centuri
could
address
vaccin
fig
past
pregnant
women
high
level
antibodi
rang
pathogen
expos
transfer
protect
immun
unborn
fetu
newborn
babi
via
transplacent
transfer
antibodi
breast
feed
today
young
women
less
expos
infecti
agent
breast
feed
less
common
shorter
durat
therefor
mother
transfer
fewer
protect
antibodi
infant
consequ
newborn
protect
variou
pathogen
diseas
includ
cytomegaloviru
influenza
viru
group
b
streptococcu
hepat
b
viru
meningococcu
group
b
c
pertussi
respiratori
syncyti
viru
tetanu
except
hepat
b
viru
vaccin
bacil
bcg
countri
given
birth
present
immun
schedul
start
mostli
two
month
age
consequ
present
immun
schedul
induc
protect
major
diseas
fifth
month
life
later
leav
period
vulner
first
month
life
associ
signific
mortal
morbid
recent
increas
frequenc
pertussi
case
subsequ
mortal
infant
younger
month
exampl
trend
recent
success
involv
vaccin
pregnant
women
neonat
tetanu
influenza
viru
order
promot
immun
neonat
shown
vaccin
birth
safe
effect
provid
newborn
mother
protect
pathogen
studi
show
vaccin
promot
natur
immun
protect
newborn
human
evolut
select
weaken
result
decreas
exposur
mother
infecti
agent
vaccin
discuss
alreadi
avail
vaccin
meningococcu
respiratori
syncyti
viru
group
b
streptococcu
develop
believ
children
twentyfirst
centuri
wellprotect
first
month
life
vaccin
mother
age
group
one
bestserv
present
vaccin
schedul
current
recommend
children
immun
diphtheria
tetanu
pertussi
hepat
b
viru
h
influenza
type
b
polioviru
streptococcu
pneumonia
rotaviru
measl
mump
rubella
fig
immun
schedul
remain
place
immun
meningococcu
respiratori
syncyti
viru
influenza
viru
group
streptococcu
helicobact
pylori
ad
schedul
vaccin
becom
avail
vaccin
hepat
viru
also
ad
schedul
importantli
proper
programm
matern
immun
implement
possibl
relax
aggress
immun
schedul
today
children
receiv
immun
month
age
month
age
although
schedul
design
induc
protect
immun
earli
life
optim
effect
prime
stillimmatur
immun
system
better
prime
differ
regim
immun
month
booster
month
may
consid
need
howev
ensur
matern
immun
interfer
infant
vaccin
sinc
well
known
presenc
matern
antibodi
prevent
infant
mount
optim
immun
respons
liveattenu
viral
vaccin
use
measl
interf
viral
replic
effect
usual
present
even
case
report
inactiv
vaccin
wholecel
pertussi
therefor
presenc
need
assess
new
vaccin
adolesc
countri
vaccin
human
papilloma
viru
meningococcu
serogroup
c
alreadi
recommend
adolesc
addit
adolesc
could
receiv
booster
vaccin
diphtheria
tetanu
pertussi
booster
vaccin
influenza
viru
meningo
coccu
group
b
becom
avail
immun
epsteinbarr
viru
herp
simplex
viru
cytomegaloviru
parvoviru
also
desir
vaccin
becom
avail
adult
current
adult
countri
receiv
schedul
vaccin
tetanu
influenza
howev
mani
time
vaccin
special
circumst
work
potenti
infect
human
sampl
travel
diseaseaffect
area
averag
life
expect
individu
societi
vaccin
develop
year
societi
character
high
proport
children
young
peopl
quit
differ
today
societi
character
high
proport
elderli
peopl
life
expect
year
discuss
detail
howev
immun
schedul
establish
adult
includ
vaccin
emerg
strain
influenza
viru
period
boost
maintain
immun
diphtheria
tetanu
pertussi
hepat
b
viru
respiratori
syncyti
viru
meningococcu
group
b
c
import
target
group
develop
new
vaccin
elderli
demograph
group
vaccin
fulli
exploit
yet
popul
sever
new
medic
need
first
age
immun
system
make
vulner
mani
infect
previous
immun
suscept
infect
influenza
viru
meningococcu
group
b
streptococcu
pneumococcu
respiratori
syncyti
viru
varicella
zoster
viru
becom
higher
age
group
need
morefrequ
booster
vaccin
mani
case
vaccin
potenti
adjuv
specif
design
stimul
age
immun
system
respond
better
vaccin
one
exampl
licens
adjuv
effici
use
boost
immun
respons
elderli
oilinwat
emuls
novarti
licens
use
adjuv
season
influenza
vaccin
european
countri
sever
countri
shown
reduc
hospit
elderli
licens
experiment
adjuv
good
candid
novel
vaccin
elderli
patient
futur
tabl
second
medic
need
elderli
immun
antibioticresist
bacteria
acquir
hospitalizationthes
infect
frequent
age
group
therefor
would
use
anoth
import
medic
need
popul
strategi
prevent
cancer
risk
cancer
increas
age
question
whether
prevent
delay
age
cancer
strike
tumour
caus
infecti
agent
certain
liver
cervic
stomach
cancer
elimin
prevent
infect
vaccin
addit
cancer
associ
infecti
agent
breast
colorect
prostat
cancer
could
prevent
vaccin
self
antigen
preferenti
express
tumour
cell
antigen
lactalbumin
human
epiderm
growth
factor
receptor
also
known
neu
shown
work
vaccin
target
anim
model
breast
cancer
addit
vaccin
target
mucin
shown
promis
colorect
cancer
earli
trial
sever
antigen
evalu
prostat
cancer
vaccin
would
induc
protect
immun
tumour
format
abl
provid
earli
protect
emerg
tumour
requir
identif
antigen
provid
protect
without
induc
undesir
autoimmun
phenomena
addit
vaccin
requir
differ
age
group
number
group
peopl
distinct
need
requir
special
consider
fig
travel
age
vaccin
diseas
may
find
area
travel
vaccin
follow
pathogen
diseas
consid
travel
cholera
dengu
enterotoxigen
e
coli
etec
influenza
viru
hepat
viru
hepat
b
viru
japanes
enceph
viru
malaria
meningococcu
group
b
c
w
x
paratyphoid
fever
rabi
shigella
spp
tickborn
enceph
viru
tuberculosi
typhoid
fever
yellow
fever
although
vaccin
exist
sever
diseas
signific
need
effect
vaccin
dengu
cholera
etec
malaria
shigella
spp
paratyphoid
fever
addit
travel
would
benefit
safer
vaccin
yellow
fever
moreeffect
vaccin
typhoid
fever
patient
chronic
diseas
peopl
chronic
diseas
autoimmun
diseas
immunosuppress
disord
individu
chronic
respiratori
cardiac
diseas
special
vaccin
need
specif
condit
vaccin
consid
includ
cytomegaloviru
influenza
viru
fungal
infect
caus
aspergillu
spp
candida
spp
parainfluenza
p
aeruginosa
respiratori
syncyti
viru
aureu
tuberculosi
patient
hereditari
haemoglobinopathi
sicklecel
anaemia
protect
infect
parvoviru
patient
hiv
may
also
consid
vaccin
influenza
viru
pneumococcu
pneumocystosi
tuberculosi
howev
subject
immunocompromis
mani
liveattenu
vaccin
may
danger
well
toler
therefor
subunit
vaccin
possibl
support
potent
adjuv
may
requir
elicit
protect
respons
addit
sever
infecti
diseas
caus
signific
morbid
mortal
malaria
hiv
resist
attempt
develop
effect
vaccin
growth
human
popul
global
travel
chang
planet
ecosystem
suggest
novel
infecti
diseas
continu
emerg
mani
case
possibl
control
emerg
threat
vaccin
howev
requir
coordin
effort
involv
public
privat
sector
regulatori
agenc
ensur
appropri
technolog
manufactur
capac
financi
resourc
avail
need
exampl
public
privat
sector
combin
resourc
fight
emerg
infect
includ
path
malaria
vaccin
initi
mvi
global
hiv
vaccin
enterpris
tuberculosi
initi
aera
prepar
pandem
influenza
mvi
path
initi
develop
malaria
vaccin
advanc
programm
one
collabor
glaxosmithklin
sporozoit
antigen
rt
adjuv
combin
liposom
saponin
call
monophosphoryl
lipid
mpl
goal
assur
effici
develop
effect
vaccin
collabor
player
aera
nonprofit
initi
dedic
develop
novel
intern
vaccin
institut
intern
vaccin
institut
ivi
base
seoul
republ
korea
intern
centr
research
train
assist
vaccin
need
develop
countri
establish
unit
nation
develop
program
support
countri
world
health
organ
past
year
ivi
creat
multin
team
scientist
establish
programm
vaccin
japanes
enceph
viru
enter
infect
shigella
spp
cholera
salmonella
institut
largest
success
format
collabor
network
studi
epidemiolog
vaccin
impact
diseas
asian
children
led
establish
diseas
burden
mening
caus
haemophilu
influenza
type
b
streptococcu
pneumonia
meningococcu
implement
h
influenza
b
vaccin
mani
countri
institut
present
expand
epidemiolog
vaccin
clinic
studi
africa
latin
america
novarti
vaccin
institut
global
health
novarti
vaccin
institut
global
health
nvgh
locat
siena
itali
establish
novarti
foundat
mission
develop
vaccin
need
lowincom
countri
develop
innov
vaccin
manufactur
absenc
market
institut
nonprofit
mission
first
entiti
type
set
vaccin
compani
institut
access
technolog
knowledg
novarti
vaccin
diagnost
compani
uniqu
asset
avail
public
institut
provid
potenti
develop
stateoftheart
innov
vaccin
nvgh
focus
diarrhoeal
diseas
caus
salmonella
typhi
salmonella
paratyphi
salmonella
enterica
salmonella
typhimurium
shigella
spp
less
three
year
establish
nvgh
develop
test
clinic
phase
phase
ii
trial
conjug
vaccin
typhi
vaccin
paratyphi
late
preclin
studi
sabin
vaccin
institut
sabin
vaccin
institut
locat
washington
dc
usa
nonprofit
organ
mission
reduc
human
suffer
caus
vaccineprevent
neglect
tropic
diseas
establish
institut
programm
develop
vaccin
human
hookworm
schistosomiasi
malaria
advanc
programm
human
hookworm
diseas
affect
million
peopl
vaccin
test
sever
clinic
trial
hilleman
laboratori
hilleman
laboratori
announc
repres
merck
wellcom
trust
vision
develop
vaccin
diseas
preval
lowincom
countri
first
time
chariti
pharmaceut
compani
partner
form
joint
ventur
type
institut
locat
india
mission
develop
new
vaccin
optim
deliveri
exist
vaccin
hilleman
laboratori
oper
nonprofit
entiti
engag
discoveri
research
instead
focu
phase
phase
ii
product
develop
tuberculosi
vaccin
organ
plan
perform
sever
clinic
trial
test
efficaci
new
vaccin
near
futur
case
avian
influenza
public
sector
sponsor
clinic
trial
develop
novel
technolog
vaccin
manufactur
product
influenza
vaccin
cell
cultur
technolog
advanc
appli
season
influenza
vaccin
could
provid
influenza
vaccin
rapidli
avail
safer
case
emerg
infect
requir
fast
develop
new
vaccin
novel
adjuv
key
role
great
exampl
recent
pandem
influenza
caus
viru
instanc
avail
licens
oilinwat
emuls
adjuv
glaxosmithklin
see
tabl
licens
adjuv
allow
product
dose
vaccin
reduc
quantiti
antigen
need
vaccin
dose
result
effect
vaccin
age
group
addit
benefit
adjuv
possibl
anticip
pandem
instanc
today
possibl
prevent
risk
avian
influenza
prime
popul
adjuv
vaccin
contain
strain
vaccin
old
viru
human
longer
immun
viru
still
circul
bird
pig
could
cross
speci
barrier
newli
introduc
human
happen
ref
howev
overal
even
expand
cell
cultur
product
capac
use
adjuv
would
suffic
produc
vaccin
entir
world
popul
approxim
seven
billion
peopl
time
manner
case
new
rapidli
spread
pandem
diseas
agent
therefor
continu
research
novel
technolog
recombin
vector
nucleicbas
synthet
vaccin
remain
prioriti
infecti
diseas
major
caus
poverti
studi
publish
scienc
ref
found
subsaharan
africa
case
meningococc
mening
strike
famili
entir
famili
incom
sever
year
spent
take
care
sick
famili
member
caus
spiral
poverti
famili
never
recov
convers
case
famili
remain
free
infecti
diseas
could
build
sustain
econom
basi
recent
speech
address
world
health
assembl
bill
gate
said
healthi
peopl
drive
thrive
economi
ref
vaccin
far
effect
tool
quickli
elimin
infecti
diseas
lowincom
countri
provid
opportun
fight
poverti
mani
exampl
meningococcu
c
vaccin
campaign
unit
kingdom
recent
vaccin
meningococcu
africa
success
vaccin
campaign
elimin
diseas
entir
countri
within
one
year
number
vaccin
need
help
fight
poverti
lowincom
countri
fig
vaccin
alreadi
avail
soon
highincom
countri
includ
vaccin
hepat
viru
hepat
b
viru
influenza
viru
meningococcu
serogroup
b
c
rabi
rotaviru
yellow
fever
viru
vaccin
may
necessari
highincom
societi
urgent
need
lowincom
countri
includ
vaccin
cholera
dengu
etec
japanes
enceph
viru
hepat
e
malaria
meningococcu
x
parasit
infect
salmonella
typhi
salmonella
paratyphi
salmonella
typhimurium
salmonella
enterica
shigella
spp
tuberculosi
today
two
main
obstacl
develop
vaccin
lowincom
countri
first
societi
mechan
develop
vaccin
need
lowincom
countri
market
highincom
countri
second
vaccin
also
medic
need
highincom
countri
optim
mostli
medic
need
countri
suboptim
medic
need
lowincom
countri
instanc
polio
rotaviru
vaccin
less
effect
develop
world
furthermor
vaccin
becam
avail
lowincom
countri
year
introduct
highincom
countri
recent
first
time
initi
launch
effect
address
problem
exampl
organ
project
aim
develop
vaccin
specif
lowincom
countri
intern
vaccin
institut
korea
novarti
vaccin
institut
global
health
sabin
vaccin
institut
hilleman
laboratori
mening
vaccin
project
mission
activ
describ
box
progress
also
made
develop
mechan
acceler
avail
exist
vaccin
lowincom
countri
innov
mechan
pneumococc
advanc
market
commit
amc
gavi
allianc
initi
five
countri
canada
itali
norway
russia
unit
kingdom
bill
melinda
gate
foundat
commit
us
billion
purchas
newli
develop
pneumococcu
vaccin
make
avail
countri
afford
although
initi
show
make
progress
field
much
stronger
coordin
public
sector
privat
sector
regulatori
bodi
fund
agenc
necessari
make
impact
short
term
captur
uniqu
opportun
provid
good
health
everi
human
tabl
either
alon
combin
differ
class
adjuv
alum
emuls
saponin
liposom
fast
develop
new
technolog
tabl
suggest
soon
abl
develop
effect
vaccin
mani
new
pathogen
improv
safeti
efficaci
exist
vaccin
start
tackl
novel
target
treatment
diseas
chronic
infecti
diseas
cancer
believ
vaccin
import
societi
twentyfirst
centuri
twentieth
centuri
even
serv
everi
age
group
becom
effici
life
insur
twentyfirst
centuri
contribut
diseasefre
life
longer
durat
better
qualiti
mani
member
modern
societi
addit
believ
medium
term
progress
scientist
make
understand
immun
system
enabl
develop
therapeut
vaccin
fight
preexist
diseas
result
chronic
infect
cancer
